Loading
In this retrospective study, women who took an aromatase inhibitor or other hormonal therapy after first-line surgery and chemotherapy for low-grade serous ovarian cancer had a median progression-free survival of over five years compared with about two years with observation.
Retrospective analysis of 203 women with stage II to IV low-grade serous carcinoma treated with primary surgery and platinum-based chemotherapy, comparing those who received hormonal maintenance therapy (mostly letrozole) with those observed.
Median progression-free survival was 64.9 months with hormonal maintenance against 26.4 months with observation, with the benefit maintained in women without residual disease and in a multivariable analysis.
Letrozole maintenance after first-line therapy is now common practice and guideline-supported for low-grade serous ovarian cancer, and the randomised NRG-GY019 trial is testing letrozole alone.
Shares David M. Gershenson, Low-grade serous ovarian cancer.
Shares Low-grade serous ovarian cancer, Journal of Clinical Oncology.